98%
921
2 minutes
20
Introduction: The renal resistive index (RRI) has been widely shown to be related with subclinical vascular damage in individuals with essential hypertension, as well as in other populations. However, limited data exist regarding the association between RRI and cardiovascular (CV) events in hypertensive individuals. Additionally, it is unclear whether the 10-year risk of CV disease, as predicted by validated score equations, is associated with impaired intrarenal hemodynamics.
Aim: The aim of our study was to analyze the relationship between RRI and both the FS and ASCVD in hypertensive individuals with no history of CV events.
Methods: A total of 742 individuals with essential hypertension (40-75 years) were enrolled. RRI was assessed in all patients using Duplex-Doppler ultrasonography, and the 10-year risk of cardiovascular disease was calculated using both the Framingham risk score (FS) and atherosclerotic cardiovascular disease risk score (ASCVD) through validated equations.
Results: Higher RRI values were observed in patients with calculated CV risk ≥ 20% compared to those with lower risk (all p < 0.001). RRI was closely associated with both FS and ASCVD scores in the overall cohort (all p < 0.001), with no significantly differences between groups with glomerular filtration rate ≥ or < 60 mL/min/1.73m. In multivariate analyses, these associations remained significant after adjusting for traditional risk factors included in the FS and ASCVD equations (p = 0.007 and p = 0.047, respectively). Receiver-operating characteristic curves indicated that RRI values >0.67 and >0.65 were associated with a high CV risk (≥ 20%), as calculated through FS and ASCVD equations, respectively.
Conclusion: RRI can be considered a marker of overall CV risk in hypertensive patients, independent of renal function.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s40292-025-00714-z | DOI Listing |
Genet Med
September 2025
Institute for Clinical and Translational Science, University of California, Irvine, CA, USA.
Purpose: Advancements in sequencing technologies have significantly improved clinical genetic testing, yet the diagnostic yield remains around 30-40%. Emerging technologies are now being deployed to address the remaining diagnostic gap.
Methods: We tested whether short-read genome sequencing could increase the diagnostic yield in individuals enrolled into the UCI-GREGoR research study, who had suspected Mendelian conditions and prior inconclusive testing.
Protein Cell
August 2025
Department of Neurology and National Center for Neurological Disorders, Huashan Hospital, State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Fudan University, Shanghai 200433, China.
Cardiovascular disease (CVD) research is hindered by limited comprehensive analyses of plasma proteome across disease subtypes. Here, we systematically investigated the associations between plasma proteins and cardiovascular outcomes in 53,026 UK Biobank participants over a 14-year follow-up. Association analyses identified 3,089 significant associations involving 892 unique protein analytes across 13 CVD outcomes.
View Article and Find Full Text PDFHealth Inf Manag
September 2025
Health Information Technology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Background: The success of disease registry systems (DRSs) depends on developing software that aligns with the registry's specific needs.
Objective: This study focuses on localising the Checklist with Items for Patient Registry sOftware Systems (CIPROS) to facilitate the DRS assessment.
Method: This applied and cross-sectional study was carried out in 2023 in six phases.
Circulation
September 2025
Division of Cardiology, Columbia University Irving Medical Center, New York, NY (S.A.P.).
Background: Limited treatment options exist for infrapopliteal disease in patients with chronic limb-threatening ischemia (CLTI), a condition associated with a high risk of limb loss. Interventional management of diseased infrapopliteal vessels with percutaneous transluminal angioplasty (PTA) is associated with high rates of restenosis and reintervention. In the LIFE-BTK trial, the drug-eluting resorbable scaffold (DRS) demonstrated superior 12-month efficacy compared with PTA in a selected CLTI population with predominantly noncomplex, mildly to moderately calcified lesions.
View Article and Find Full Text PDFJ Intern Med
September 2025
Department of Cellular and Translational Physiology, Institute of Physiology, Ruhr University Bochum, Bochum, Germany.
Background: High-density lipoprotein (HDL) function, rather than its concentration, plays a crucial role in the development of coronary artery disease (CAD). Diminished HDL antioxidant properties, indicated by elevated oxidized HDL (nHDL) and diminished paraoxonase-1 (PON-1) activity, may contribute to vascular dysfunction and inflammation. Data on these associations in CAD patients, including acute coronary syndrome (ACS), remain limited.
View Article and Find Full Text PDF